Non Opioid Pain Drug Development Summit
In-Person Event
Sep 27 - 28, 2018
Boston, Massachusetts, USA
OVERVIEW
Non Opioid Pain Drug Development Summit is organized by Hanson Wade and will be held from Sep 27 - 28, 2018 at Wyndham Boston Beacon Hill, Boston, Massachusetts, United States of America.
This summit and its expert speaker faculty will update you on the latest and novel RandD efforts currently ongoing in discovery and optimization of non-opioid analgesic targets and their mechanism of action. In addition, the inaugural Non-Opioid Pain Drug Development Summit will be your dedicated platform to overcome translational challenges such as animal model predictive value, biomarker identification, and proving efficacy against placebo effect.
Key areas of focus:
• Non-Addictive Opioid Based Therapeutics as a Catalyst for Better Pain R&D: The challenge facing drug developers in pain drug R&D is twofold: developing new alternatives that are effective in pain management while minimizing the euphoric side effects. At our summit, find out how the latest development in non-addictive opioid pain drug development could pave your approach towards developing novel non-opioid pain drugs
• Optimizing the Validation of Novel Non-Opioid Analgesic Targets:Understanding the complex underlying mechanism of action and discovering novel analgesic targets are key to successfully develop alternative pain therapies. At our summit, find out the most cutting-edge areas of pain research in pursuit of novel target identification and validation - beyond traditional opioid receptors
• Overcoming Key Translational Hurdles:Well-designed clinical studies to demonstrate safety and significant efficacy above and beyond placebo controls and existing pain treatments is critical to reducing failure rates. At our summit hear about and delve into discussions around the development of robust pain models and clinical validation & predictively of biomarkers for optimized patient selection, recruitment and adherence
• Successful Clinical Development of Non-Opioid Pain Drugs:The long-term goal of the most of the drug developers is to develop new alternatives for pain relief that are non-addictive and non-opioid based. At our summit, through case studies and networking opportunities, widen your company’ horizon by establishing new clinical trial networks and contacts to accelerate drug development for patients with high unmet needs for pain management
Prices:
Conference + 1 Workshop Earlybird (Book by 15/06/18): USD 1798.0
Conference + 1 Workshop (standard rate): USD 2498.0
Conference Earlybird (Book by 15/06/18): USD 1299.0
Conference (Standard rate): USD 1999.0
Workshop: USD 499.0
Speakers: Mary Ann Pellymounter (NIH/NINDS/Division of Translational Research), Daniel Klamer (Anavex Life Sciences Corp.), Kerrie Brady (Centrexion Corp), Crist Frangaki (Achelios Therapeutics), Lucio Rovati (Rottapharm Biotech), Silviu Itescu (Mesoblast Ltd.)
Time: 8:00 am - 4:00 pm
Additional details will be posted as soon as they are available.
This summit and its expert speaker faculty will update you on the latest and novel RandD efforts currently ongoing in discovery and optimization of non-opioid analgesic targets and their mechanism of action. In addition, the inaugural Non-Opioid Pain Drug Development Summit will be your dedicated platform to overcome translational challenges such as animal model predictive value, biomarker identification, and proving efficacy against placebo effect.
Key areas of focus:
• Non-Addictive Opioid Based Therapeutics as a Catalyst for Better Pain R&D: The challenge facing drug developers in pain drug R&D is twofold: developing new alternatives that are effective in pain management while minimizing the euphoric side effects. At our summit, find out how the latest development in non-addictive opioid pain drug development could pave your approach towards developing novel non-opioid pain drugs
• Optimizing the Validation of Novel Non-Opioid Analgesic Targets:Understanding the complex underlying mechanism of action and discovering novel analgesic targets are key to successfully develop alternative pain therapies. At our summit, find out the most cutting-edge areas of pain research in pursuit of novel target identification and validation - beyond traditional opioid receptors
• Overcoming Key Translational Hurdles:Well-designed clinical studies to demonstrate safety and significant efficacy above and beyond placebo controls and existing pain treatments is critical to reducing failure rates. At our summit hear about and delve into discussions around the development of robust pain models and clinical validation & predictively of biomarkers for optimized patient selection, recruitment and adherence
• Successful Clinical Development of Non-Opioid Pain Drugs:The long-term goal of the most of the drug developers is to develop new alternatives for pain relief that are non-addictive and non-opioid based. At our summit, through case studies and networking opportunities, widen your company’ horizon by establishing new clinical trial networks and contacts to accelerate drug development for patients with high unmet needs for pain management
Prices:
Conference + 1 Workshop Earlybird (Book by 15/06/18): USD 1798.0
Conference + 1 Workshop (standard rate): USD 2498.0
Conference Earlybird (Book by 15/06/18): USD 1299.0
Conference (Standard rate): USD 1999.0
Workshop: USD 499.0
Speakers: Mary Ann Pellymounter (NIH/NINDS/Division of Translational Research), Daniel Klamer (Anavex Life Sciences Corp.), Kerrie Brady (Centrexion Corp), Crist Frangaki (Achelios Therapeutics), Lucio Rovati (Rottapharm Biotech), Silviu Itescu (Mesoblast Ltd.)
Time: 8:00 am - 4:00 pm
Additional details will be posted as soon as they are available.
KEY DATES
27 Sep, 2018
Event Start Date
28 Sep, 2018
Event End Date
SPECIALITIES
Pharmacy and MedicineSUGGESTED HOTELS
CONFERENCE VENUE
Wyndham Boston Beacon HillRELATED CONFERENCES & LIVE WEBINARS
Quick Links